Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

81. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. 25002178 2014 12 03 2015 02 19 2016 11 25 1474-547X 384 9957 2014 Nov 22 Lancet (London, England) Lancet Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. 1849-58 10.1016/S0140-6736(14)60924-7 S0140-6736(14)60924-7 Bivalirudin (...) , with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI). We aimed to compare antithrombotic therapy with bivalirudin or unfractionated heparin during this procedure. In our open-label, randomised controlled trial, we enrolled consecutive adults scheduled for angiography in the context of a PPCI presentation at Liverpool Heart and Chest Hospital (Liverpool, UK) with a strategy of delayed consent. Before angiography

Lancet2014

82. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup 23831445 2013 10 04 2013 12 03 2016 11 25 1558-3597 62 15 2013 Oct 08 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions (...) revealed excellent results, efficacy in long lesions remains unsatisfactory. In a prospective, randomized, single-blind, multicenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin-bonded, covered stents (Viabahn 72 patients) or BMS (69 patients). Clinical outcomes and patency rates were assessed at 1, 6, and 12 months. Mean ± SD lesion length was 19.0 ± 6.3 cm in the Viabahn group and 17.3 ± 6.6 cm in the BMS group. Major complications within 30

EvidenceUpdates2013

83. Argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) - in adult patients with heparin-induced thrombocytopenia type II

Argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) - in adult patients with heparin-induced thrombocytopenia type II

Scottish Medicines Consortium2013

85. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. BACKGROUND: The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit (...) in microvascular surgery such as digital replantation is unclear. OBJECTIVES: To assess whether subcutaneous LMWH treatment improves the salvage rate of the digits in patients with digital replantation after traumatic amputation. SEARCH METHODS: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (October 2012), CENTRAL (2012, Issue 10) and trials databases. In addition, the authors searched PubMed, CNKI (China National Knowledge Infrastructure

Cochrane2013

86. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. BACKGROUND: Sickle cell disease is one of the most common and severe genetic disorders in the world. It can be broadly divided into two distinct clinical phenotypes characterized by either haemolysis or vaso-occlusion. Pain is the most prominent symptom of vaso-occlusion, and hypercoagulability is a well-established pathogenic phenomenon in people with sickle (...) cell disease. Low-molecular-weight heparins might control this hypercoagulable state through their anticoagulant effect. OBJECTIVES: To assess the effects of low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches. We also searched abstract books of conference proceedings and several online

Cochrane2013

87. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. BACKGROUND: The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE: To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN: Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically

Annals of Internal Medicine2013

88. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial

Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2013

89. Methods for administering subcutaneous heparin during pregnancy.

Methods for administering subcutaneous heparin during pregnancy. BACKGROUND: Pregnant women with a history of venous thromboembolism (VTE), antithrombin deficiency, or other risk factors for VTE, need heparin (unfractionated heparin (UFH) or low-molecular weight heparin (LMWH)) prophylaxis, mainly through administering subcutaneously. Several methods of administering heparin (UFH or LMWH) subcutaneously have been introduced to prevent adverse pregnant outcomes. The effectiveness and safety (...) of different methods administering subcutaneous heparin (UFH or LMWH) during pregnancy have not been systematically evaluated. OBJECTIVES: To compare the effectiveness and safety of different methods of administering subcutaneous heparin (UFH or LMWH) to pregnant women. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2013) and reference lists of retrieved studies. SELECTION CRITERIA: All randomised controlled trials (individual and cluster) comparing

Cochrane2013

90. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW CRD summary This review found (...) that citrate for continuous renal replacement therapy was similar to heparin anticoagulation treatment in patients with acute kidney injury and reductions in bleeding risk were observed. The review was well conducted but the poor quality of the included trials means the authors conclusions should be interpreted with some caution and the reliability of the conclusions is unclear. Authors' objectives To compare the efficacy and safety of regional citrate treatment with heparin anticoagulation for continuous

DARE.2013

91. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Extended out-of-hospital low-mole... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2001 ) Volume: 135 , Issue: 10 , Publisher: Am Coll Physicians , Pages: 858-69 ISSN: 00034819 PubMed: Available from or Find this paper (...) at: Abstract Evidence-based medicine guidelines based on venographic end points recommend in-hospital prophylaxis with low-molecular-weight heparin (LMWH) in patients having elective hip surgery. Emerging data suggest that out-of-hospital use may offer additional protection; however, uncertainty remains about the risk-benefit ratio. To provide clinicians with a practical pathway for translating clinical research into practice, we systematically reviewed trials comparing extended out-of-hospital LMWH

Annals of Internal Medicine2013

92. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic (...) unfractionated heparin, to prevent venous thromboembolism, after an acute ischaemic stroke. The authors concluded that the higher cost of enoxaparin was offset by fewer clinical events, compared with unfractionated heparin, particularly for patients with more severe stroke. The study focused on the economic data and was satisfactorily carried out. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-effectiveness analysis Study objective This study examined the clinical and economic

NHS Economic Evaluation Database.2013

93. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. BACKGROUND: Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk. OBJECTIVES: This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (...) (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 15 October 2012. SELECTION CRITERIA: We only included randomised controlled trials (RCTs) that compared intravitreal LMWH alone or with 5-FU, versus placebo for the prevention of postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment repair. DATA COLLECTION AND ANALYSIS: Two review authors

Cochrane2013

95. Thromboelastography-guided heparin use for the prevention of venous thromboembolism

Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Mitchell MD, Fishman N, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Fishman N (...) , Umscheid CA. Thromboelastography-guided heparin use for the prevention of venous thromboembolism. Philadelphia: Center for Evidence-based Practice (CEP). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Heparin; Humans; Venous Thromboembolism Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535

Health Technology Assessment (HTA) Database.2013

96. The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis

The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis Bochenek T, Nizankowski R CRD summary The review found that low molecular weight heparins were safer and as effective as vitamin K antagonists, for venous thromboembolism, for the general population and for cancer patients (...) . The authors' conclusions reflected the evidence presented, but limitations in the review process and reporting, and the low quality of the included trials, mean that their reliability is unclear. Authors' objectives To compare the efficacy and safety of low molecular weight heparins with vitamin K antagonists, for venous thromboembolism, in the general population, in pregnant women, and in patients with cancer. Searching Searches were made in January 2008, in MEDLINE, EMBASE, BioMed Central, The Cochrane

DARE.2012

97. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention

Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention Bertrand OF, Jolly SS, Rao SV, Patel T, Belle L, Bernat I, Parodi G, Costerousse O (...) , Mann T CRD summary This review concluded that in people undergoing transfemoral percutaneous coronary intervention, there were significantly fewer major bleeds with bivalirudin, than with unfractionated heparin, but the rates of major adverse cardiac events were similar. As there were some questions about the quality of the included data, the conclusions should be treated with caution. Authors' objectives To assess the effects of bivalirudin, compared with unfractionated heparin, for people

DARE.2012

98. Argatroban (Exembol) - anticoagulation in adult patients with heparin-induced thrombocytopenia type II

Argatroban (Exembol) - anticoagulation in adult patients with heparin-induced thrombocytopenia type II

Scottish Medicines Consortium2012

99. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines

Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Efficacy and safety of unfractionated heparin plus (...) glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Winchester DE, Brearley WD, Wen X, Park KE, Bavry AA CRD summary The review found adding glycoprotein IIb/IIIa inhibitors to unfractionated heparin reduced myocardial infarction and revascularisation rates without increasing major bleeding among patients undergoing revascularisation for acute coronary syndrome using stents

DARE.2012

100. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence

Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions No relevant studies were identified that compared the clinical

Health Technology Assessment (HTA) Database.2012